XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Oct. 03, 2025
Jan. 03, 2025
Current assets:    
Cash and cash equivalents $ 376,300 $ 217,374
Marketable securities 612,235 893,902
Trade receivables, net 309,725 265,437
Inventory 27,402 22,388
Prepaid expenses and other current assets 76,595 68,478
Total current assets 1,402,257 1,467,579
Non-current marketable securities 578,287 637,291
Property and equipment, net 104,748 119,391
Deferred tax assets, net 418,582 420,027
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 255,989 239,718
Total assets 2,823,547 2,947,690
Current liabilities:    
Accounts payable 25,348 38,191
Accrued compensation and benefits 104,364 109,830
Accrued clinical trial liabilities 57,781 57,976
Rebates and fees due to customers 58,234 62,376
Accrued collaboration liabilities 23,428 40,384
Other current liabilities 104,622 95,012
Total current liabilities 373,777 403,769
Non-current operating lease liabilities 176,463 190,823
Other non-current liabilities 112,607 108,895
Total liabilities 662,847 703,487
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 268,098 and 281,732 at September 30, 2025, and December 31, 2024, respectively 268 282
Additional paid-in-capital 2,262,928 2,343,915
Accumulated other comprehensive income (loss) 3,565 (1,347)
Accumulated deficit (106,061) (98,647)
Total stockholders’ equity 2,160,700 2,244,203
Total liabilities and stockholders’ equity $ 2,823,547 $ 2,947,690